Current Stem Cell Delivery Methods for Myocardial Repair

Table 2

Catheter-based transendocardial injection studies.

Study	No. of patients	Cell type	No. of cells	Outcome
Smits et al. (2003) [54]	5/0	SMB	2.96 × 10^8	Improvement in LVEF
Perin et al. (2004) [97]	11/9	ABMMNC	2 × 10^6	Improvement in exercise capacity and myocardial perfusion
Fuchs et al. (2006) [98]	27/0	BMC	2.8 × 10^7	Improvement in perfusion and LVEF
Briguori et al. (2006) [99]	10/0	CD34 + /CD45 + BMC	4.6 × 10^6	Improvement in myocardial perfusion
de la Fuente et al. (2007) [100]	10/0	ABMMNC	8.6 × 10^7	Improvement in LVEF
Tse et al. (2007) [101]	9/10/9	BMC	1 × 10^6/2 × 10^6	Improvement in LVEF
Van Ramshorst et al. (2009) [102]	25/25	ABMMNC	1 × 10^8	Modest improvement in myocardial perfusion
Trachtenberg (2011) [103]	40/20	MSC/BMC	2 × 10^8	Minor improvement in LVEF
Williams et al. (2011) [104]	8/0	MSC/ABMMNC	7.63 × 10^8	Improvement in regional contractility
Perin et al. (2012) [105]	61/31	BMC	1 × 10^8	No improvement in LVEF
Perin et al. (2012) [105]	10/10	ALDH^br	N/A	Improvement in cardiac function and perfusion of cardiac tissue

ABMMNC: autologous bone marrow mononuclear cells; ALDH^br: aldehyde dehydrogenase bright cells; BMC: bone marrow cells; LVEF: left ventricular ejection fraction; MSC: mesenchymal stem cells; SMB: skeletal myoblasts.